Neuropathic Ocular Pain Market, By Drug Class, By Distribution Channel, And by Region

PUBLISHED: April 29, 2026

PAGES: 250+ Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Neuropathic Ocular Pain Market is estimated to be valued at USD 216.6 Mn in 2026 and is expected to reach USD 272.4 Mn by 2033, growing at a compound annual growth rate (CAGR) of 3.3% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 216.6 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	3.30%	2033 Value Projection:	USD 272.4 Mn

Neuropathic pain is a pain condition that's usually chronic. It's usually caused by chronic, progressive nerve disease, and it can also occur as the result of injury or infection. Ocular neuropathic pain, also referred to as corneal neuropathic pain, is a condition where corneal pain is seen in response to normally non-painful stimuli. This results from repeated direct damage to corneal nerves. This damaged nerve sends pain signals to central nervous system (CNS) even in the absence of painful stimulus, thus, called "pain without stain" or "phantom cornea'. This condition is the ocular analog of systemic neuropathic pain, a complex regional pain syndrome, or reflex sympathetic dystrophy (RSD). Ocular or corneal neuropathic pain, corneal neuropathy, corneal neuralgia, kertaoneuralgia, and corneal allodynia are all terms that are used to describe the same disease entity.

Market Dynamics

An increase in government and non-government organizations' initiatives to improve access to affordable vision care and an increase in awareness among people regarding eye-related disease are expected to drive the market growth. Moreover, an increase in product launches by key market players is expected to drive the market growth over the forecast period. For instance, in November 2021, I-MED Pharma inc., a privately held Canada based eye care company, announced that it had launched an entire portfolio of dry eye products in the U.S. The products such as I-DROP, I-DEFENCE, and others, are intended to provide long-lasting relief from eye dryness, which is caused due to neuropathic ocular pain.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global neuropathic ocular pain market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include OKYO Pharma, Limited, Ocular Therapeutix, Inc., IACTA Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, SALVAT, AbbVie Inc., Bausch & Lomb Incorporated, Kala Pharmaceuticals, Spectra Vision Care, Alcon Laboratories, AERIE PHARMACEUTICALS, INC., Optocred Pharmaceuticals and BRIM Biotechnology, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global neuropathic ocular pain market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neuropathic ocular pain market

Detailed Segmentation:

Global Neuropathic Ocular Pain Market, By Drug Class (Revenue, USD Mn, 2021 - 2033)
Steroids
Non-Steroidal Anti-Inflammatory Drugs
Antidepressants
Anticonvulsants
Opioids
Others (Vitamin B supplements, Botulinum toxin A, and others)
Global Neuropathic Ocular Pain Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Neuropathic Ocular Pain Market, By Region (Revenue, USD Mn, 2021 - 2033)
North America
- By Country:
  - U.S.
  - Canada
Latin America
- By Country:
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- By Country:
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- By Country
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- By Country:
  - GCC
  - Israel
  - Rest of Middle East
Africa
- By Country/Region:
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
OKYO Pharma Limited*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
Ocular Therapeutix, Inc.
IACTA Pharmaceuticals, Inc.
Sun Pharmaceutical Industries Ltd.
Novartis AG
SALVAT
AbbVie Inc.
Bausch & Lomb Incorporated
Kala Pharmaceuticals
Spectra Vision Care.
Alcon Laboratories
AERIE PHARMACEUTICALS, INC.
Optocred Pharmaceuticals
BRIM Biotechnology, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Product Code: CMI5600

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis
Pipeline Analysis

4. Global Neuropathic Ocular Pain Market, By Drug Class, 2021 - 2033, (US$ Million)

Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Steroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Non-Steroidal Anti-Inflammatory Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Anticonvulsants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Opioids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Others (Vitamin B supplements, Botulinum toxin A, and others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

5. Global Neuropathic Ocular Pain Market, By Distribution Channel, 2021 - 2033, (US$ Million)

Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

6. Global Neuropathic Ocular Pain Market, By Region, 2021 - 2033, (US$ Million)

Overview
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Million)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

OKYO Pharma, Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Ocular Therapeutix, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
IACTA Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
SALVAT
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bausch & Lomb Incorporated
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Kala Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Spectra Vision Care
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Alcon Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
AERIE PHARMACEUTICALS, INC.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Optocred Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
BRIM Biotechnology, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies